Stock News

Jag Capital Management LLC Has Lowered Stake in Vertex Pharmaceuticals INC (VRTX) by $7.36 Million as Market Value Rose

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) LogoInvestors sentiment increased to 1.3 in 2018 Q2. Its up 0.15, from 1.15 in 2018Q1. It improved, as 34 investors sold VRTX shares while 176 reduced holdings. 61 funds opened positions while 211 raised stakes. 236.55 million shares or 1.64% more from 232.72 million shares in 2018Q1 were reported. Cambridge Investment Research Advisors has invested 0.01% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Baldwin Brothers Ma stated it has 0.03% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Louisiana State Employees Retirement System invested in 15,000 shares or 0.11% of the stock. Checchi Cap Advisers Limited Liability Co reported 1,560 shares. M&T National Bank, New York-based fund reported 20,859 shares. Cetera Limited holds 0.03% or 3,181 shares. Hudson Bay Capital Mngmt Limited Partnership accumulated 30,000 shares. Landscape Mgmt Ltd Liability Co, New Jersey-based fund reported 2,371 shares. State Treasurer State Of Michigan reported 75,468 shares or 0.1% of all its holdings. Amer Research And Management reported 11,100 shares. 134,294 were accumulated by Amp Investors Limited. Bluemountain Cap Management Ltd reported 42,882 shares stake. State Of Tennessee Treasury Department holds 0.24% or 273,198 shares in its portfolio. Shell Asset Mgmt stated it has 24,800 shares. Meeder Asset Mgmt Incorporated, a Ohio-based fund reported 29,461 shares.

Since May 15, 2018, it had 0 insider buys, and 19 selling transactions for $37.73 million activity. ALTSHULER DAVID also sold $4.25M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares. $3.89 million worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by SMITH IAN F. 140,211 shares were sold by LEIDEN JEFFREY M, worth $22.43M on Friday, June 22. Sachdev Amit sold $2.48 million worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Friday, July 13. The insider Parini Michael sold 85 shares worth $13,241. Arbuckle Stuart A also sold $626,652 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares.

Jag Capital Management Llc decreased its stake in Vertex Pharmaceuticals Inc. (VRTX) by 71.11% based on its latest 2018Q2 regulatory filing with the SEC. Jag Capital Management Llc sold 43,560 shares as the company’s stock rose 17.38% with the market. The institutional investor held 17,695 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $3.01 million, down from 61,255 at the end of the previous reported quarter. Jag Capital Management Llc who had been investing in Vertex Pharmaceuticals Inc. for a number of months, seems to be less bullish one the $46.14 billion market cap company. The stock increased 0.16% or $0.29 during the last trading session, reaching $180.55. About 1.85M shares traded or 48.19% up from the average. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 13.72% since November 10, 2017 and is uptrending. It has underperformed by 1.90% the S&P500.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Nasdaq.com which released: “10 Strong Buy Stocks Trading at Killer Entry Points” on November 08, 2018, also Seekingalpha.com with their article: “Vertex Q3 revenues up 36%; earnings up 225%” published on October 24, 2018, Fool.com published: “AbbVie Takes Aim at Vertex Pharmaceuticals Incorporated” on October 27, 2018. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Fool.com and their article: “Vertex Pharmaceuticals Waits to Hit the Triple” published on October 29, 2018 as well as Seekingalpha.com‘s news article titled: “Vertex Pharma’s Symkevi OK’d in Europe” with publication date: November 01, 2018.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 7 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Vertex Pharmaceuticals had 7 analyst reports since July 26, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Monday, July 30 by Citigroup. As per Thursday, July 26, the company rating was maintained by Morgan Stanley. The rating was upgraded by H.C. Wainwright on Friday, October 26 to “Buy”. UBS maintained the shares of VRTX in report on Thursday, July 26 with “Neutral” rating. The firm has “Outperform” rating given on Thursday, October 25 by Raymond James. On Thursday, October 25 the stock rating was maintained by BMO Capital Markets with “Outperform”.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*